T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mondelez International
MDLZ
|
+$841M |
| 2 |
Liberty Global Class C
LBTYK
|
+$752M |
| 3 |
Apple
AAPL
|
+$720M |
| 4 |
Tesla
TSLA
|
+$713M |
| 5 |
NXP Semiconductors
NXPI
|
+$648M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$1.2B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.03B |
| 3 |
Gilead Sciences
GILD
|
+$917M |
| 4 |
Pfizer
PFE
|
+$901M |
| 5 |
Nike
NKE
|
+$872M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.88% |
| 2 | Consumer Discretionary | 14.86% |
| 3 | Financials | 14.2% |
| 4 | Technology | 12.51% |
| 5 | Industrials | 9.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
UBP
1551
DELISTED
Urstadt Biddle Properties Inc.
UBP
| $1.71M | ﹤0.01% |
78,320
| – | – |
|
1552
Novartis
NVS
$288B
| $1.7M | ﹤0.01% |
22,935
+480
| +2% | +$33.2K |
|
|
ENH
1553
DELISTED
Endurance Specialty Holdings Ltd
ENH
| $1.69M | ﹤0.01% |
25,124
-4,190
| -14% | -$275K |
|
1554
Spire
SR
$4.9B
| $1.68M | ﹤0.01% |
23,689
+129
| +0.5% | +$8.48K |
|
|
HTS
1555
DELISTED
HATTERAS FINANCIAL CORP
HTS
| $1.67M | ﹤0.01% |
102,050
+16,200
| +19% | +$258K |
|
1556
Ryman Hospitality Properties
RHP
$7.87B
| $1.67M | ﹤0.01% |
32,935
+5,076
| +18% | +$257K |
|
|
CCP
1557
DELISTED
Care Capital Properties, Inc.
CCP
| $1.67M | ﹤0.01% |
63,535
+17,700
| +39% | +$464K |
|
|
UNIT
1558
Uniti Group
UNIT
$2.38B
| $1.66M | ﹤0.01% |
57,578
+6,831
| +13% | +$169K |
|
|
CBI
1559
DELISTED
Chicago Bridge & Iron Nv
CBI
| $1.66M | ﹤0.01% |
48,063
+8,792
| +22% | +$325K |
|
1560
AptarGroup
ATR
$8.43B
| $1.66M | ﹤0.01% |
20,940
+143
| +0.7% | +$11.1K |
|
1561
Patterson-UTI
PTEN
$4.16B
| $1.64M | ﹤0.01% |
76,968
-5,762
| -7% | -$109K |
|
1562
Kornit Digital
KRNT
$827M
| $1.64M | ﹤0.01% |
167,687
| – | – |
|
|
STR
1563
DELISTED
QUESTAR CORP
STR
| $1.64M | ﹤0.01% |
64,490
-4,100
| -6% | -$103K |
|
|
OA
1564
DELISTED
Orbital ATK, Inc.
OA
| $1.63M | ﹤0.01% |
19,098
+7
| +0% | +$610 |
|
|
SKX
1565
DELISTED
Skechers
SKX
| $1.62M | ﹤0.01% |
54,639
+4,965
| +10% | +$150K |
|
|
DXYN
1566
DELISTED
Dixie Group Inc
DXYN
| $1.62M | ﹤0.01% |
454,591
-1,001,939
| -69% | -$3.86M |
|
|
FPRX
1567
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $1.61M | ﹤0.01% |
+39,045
| New | +$1.7M |
|
|
UN
1568
DELISTED
Unilever NV New York Registry Shares
UN
| $1.61M | ﹤0.01% |
34,249
| – | – |
|
|
AFI
1569
DELISTED
Armstrong Flooring, Inc.
AFI
| $1.6M | ﹤0.01% |
+94,514
| New | +$1.52M |
|
|
SPR
1570
DELISTED
Spirit AeroSystems
SPR
| $1.59M | ﹤0.01% |
36,932
+2,299
| +7% | +$106K |
|
1571
JetBlue
JBLU
$2.19B
| $1.57M | ﹤0.01% |
94,907
-12,951
| -12% | -$241K |
|
1572
iShares MSCI EAFE ETF
EFA
$80.3B
| $1.57M | ﹤0.01% |
28,115
+1,765
| +7% | +$102K |
|
|
CVA
1573
DELISTED
Covanta Holding Corporation
CVA
| $1.56M | ﹤0.01% |
95,062
+24,000
| +34% | +$396K |
|
1574
Cracker Barrel
CBRL
$1.31B
| $1.55M | ﹤0.01% |
9,060
+10
| +0.1% | +$1.56K |
|
|
ABMD
1575
DELISTED
Abiomed Inc
ABMD
| $1.55M | ﹤0.01% |
14,212
-1,588
| -10% | -$158K |
|
Similar funds
T. Rowe Price Associates's Q2 2016 Portfolio in Review
As of Q2 2016, T. Rowe Price Associates held 2,596 positions worth $472B, up 0.75% from $468B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
T. Rowe Price Associates's Q2 2016 filing shows 95 new, 1,094 increased, 954 reduced and 84 closed positions. Its largest new stake was American Tower Corporation: 2,223,765 shares worth $246M. The largest sale was Alexion Pharmaceuticals, an estimated $1.2B.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2016 buy was American Tower Corporation: 2,223,765 shares worth $246M.
- T. Rowe Price Associates added most to Mondelez International in Q2 2016, an estimated $841M increase.
- T. Rowe Price Associates's biggest Q2 2016 reduction was Alexion Pharmaceuticals, cutting an estimated $1.2B.
- T. Rowe Price Associates fully exited BAXALTA INC COM STK (DE) in Q2 2016, selling an estimated $750M.
- T. Rowe Price Associates's ten largest holdings make up 16% of its $472B portfolio in Q2 2016.
- T. Rowe Price Associates opened 95 new positions and closed 84 in Q2 2016.
- T. Rowe Price Associates's portfolio value rose 0.75% quarter-over-quarter to $472B.
Based on T. Rowe Price Associates's 13F filing for Q2 2016, filed 15 Aug 2016.